The major outcome trials
Cardiovascular outcome trials (CVOTs) test whether a medication reduces real-world cardiovascular events, not just lab values. They require thousands of patients, years of follow-up, and pre-specified outcomes (heart attack, stroke, cardiovascular death). For GLP-1 therapy, the major CVOTs include:
- LEADER (liraglutide), 9,340 patients, ~13% MACE reduction
- SUSTAIN-6 (semaglutide), 3,297 patients, 26% MACE reduction
- REWIND (dulaglutide), 9,901 patients, 12% MACE reduction
- SURPASS-CVOT (tirzepatide), ongoing, interim signals positive
- SELECT (semaglutide in non-diabetics with CV disease), 17,604 patients, 20% MACE reduction
The consistency across multiple molecules and patient populations argues for a class effect, not a peculiarity of any single drug.
Magnitude of benefit
14-20% relative risk reduction in major cardiovascular events translates to roughly:
- 1-2 fewer cardiovascular events per 100 patients treated for 3-5 years
- Effect compounds over longer follow-up
- Comparable in magnitude to high-intensity statin therapy
For high-risk patients (established cardiovascular disease), the absolute benefit is larger. For lower-risk populations, the relative reduction is similar but absolute numbers are smaller.
Timeline of benefit
Cardiovascular benefit appears within the first year of therapy, before substantial weight loss has occurred. This is one of the cleanest pieces of evidence that the benefit isn't simply downstream of weight loss, it's the medication producing direct vascular and inflammatory effects on a faster timeline.
Mechanisms
Multiple parallel contributions:
- Reduced inflammation, covered in detail in GLP-1 and inflammation
- Blood pressure reduction, typically 5-7 mmHg systolic
- Lipid improvements, lower triglycerides, modest ApoB reduction
- Improved endothelial function, direct vascular effect
- Weight loss, secondary contribution
- Glycemic improvement, secondary contribution
- Reduced sleep apnea severity, covered in SURMOUNT-OSA review
Blood pressure
GLP-1 therapy reduces blood pressure modestly through multiple mechanisms: weight loss, reduced sodium retention, improved endothelial function, and direct vasodilation. The 5-7 mmHg systolic reduction is comparable to a moderate-strength antihypertensive. For patients on borderline-controlled hypertension, dose adjustment of antihypertensives may be needed during therapy.
Lipid changes
Triglycerides typically drop substantially (often 20-30%). LDL-C may modestly improve. HDL-C may modestly improve. ApoB, the cleaner cardiovascular marker, often improves moderately. The lipid signature is favorable but less dramatic than the inflammatory and metabolic improvements.
SELECT in non-diabetics
The SELECT trial deserves emphasis. It tested semaglutide in 17,604 patients with established cardiovascular disease who had overweight or obesity but did NOT have diabetes. Result: 20% reduction in MACE over 3+ years. This was the first definitive demonstration that GLP-1 therapy reduces cardiovascular events in non-diabetic patients with cardiovascular risk, expanding the indication and the evidence base substantially.
What this means clinically
For OPTML patients with cardiovascular risk factors (elevated ApoB, hypertension, prior cardiac events, family history), GLP-1 therapy now sits alongside statins and antihypertensives as a cardiovascular-risk-reducing intervention, not just a weight-loss tool. The combination of weight loss, lipid improvement, blood pressure reduction, inflammation reduction, and direct vascular effects compounds substantially.
The clinical insight: The cardiovascular benefit of GLP-1 therapy appears within the first year, before significant weight loss has occurred. This is the cleanest evidence that the medication has direct vascular effects beyond its metabolic effects.
Bottom line
GLP-1 therapy reduces major adverse cardiovascular events by 14-20% across multiple trials in different patient populations, including non-diabetics with cardiovascular risk. Mechanisms include direct vascular effects, inflammation reduction, blood pressure improvement, lipid changes, and weight loss. The medication is now a recognized cardiovascular-risk-reducing therapy.